A Phase I Study of Weekly Low-Dose Cisplatin Plus Escalating Doses of Oral RAD001(Everolimus) for Patients With Advanced Solid Tumors.
Latest Information Update: 03 Oct 2021
At a glance
- Drugs Everolimus (Primary) ; Cisplatin
- Indications Solid tumours
- Focus Adverse reactions
- 19 Apr 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov. (NCT00423865)
- 19 Apr 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov. (NCT00423865)
- 19 Apr 2012 Actual end date (1 Sep 2011) added as reported by ClinicalTrials.gov. (NCT00423865)